Market Overview
Liquid embolic agents are biocompatible substances, primarily cyanoacrylate-based adhesives and ethylene vinyl alcohol copolymer solutions, injected through catheters to occlude target blood vessels. The global market encompasses products used across neurology, oncology, and interventional radiology specialties, with Onyx (ethylene vinyl alcohol copolymer) and NBCA (n-butyl cyanoacrylate) representing dominant product categories in clinical practice.
- •Market valued at approximately $282 million globally in 2025
- •Projected CAGR of 9.92% through the early 2030s
- •Primary applications include neurovascular embolization, tumor embolotherapy, and hemorrhage control
Growth Drivers
Rising incidence of stroke, brain aneurysms, and cerebrovascular disorders is increasing demand for embolization procedures, while aging populations worldwide are driving higher rates of vascular disease requiring intervention. Technological innovations in catheter-based delivery systems and the development of next-generation embolic materials with improved controllability and biocompatibility are expanding the range of treatable conditions and fueling adoption.
- •Growing burden of neurovascular diseases including AVMs, aneurysms, and ischemic stroke
- •Shift toward minimally invasive procedures offering reduced recovery times and lower complication rates
- •Advancements in imaging guidance and embolic material formulations improving procedural outcomes
Segmentation and Regional Analysis
The market is segmented by product type into cyanoacrylate adhesives, ethylene vinyl alcohol copolymer solutions, and other liquid embolics, with neurological applications representing the largest segment. Geographically, North America holds the largest market share due to advanced healthcare infrastructure and high procedure volumes, while Asia-Pacific is expected to exhibit the fastest growth driven by expanding healthcare access and rising disease prevalence.
- •Neurovascular applications account for the majority of market revenue
- •North America leads globally, supported by high adoption of minimally invasive techniques
- •Asia-Pacific emerging as fastest-growing region due to healthcare infrastructure expansion
Trends and Outlook
What are the recent trends and outlook?
The market is moving toward precision embolization with agents designed for controlled polymerization and targeted vessel occlusion, as well as increasing integration of advanced imaging modalities during procedures. Regulatory approvals for novel embolic substances in oncology applications, particularly in liver cancer embolotherapy, are expected to broaden the addressable market. Continued clinical research demonstrating superior outcomes for embolization versus traditional surgery supports sustained long-term growth.
- •Development of liquid embolics with enhanced radiopacity and controlled degradation profiles
- •Expanding oncology applications in transarterial chemoembolization and radioembolization
- •Pipeline products targeting pediatric and peripheral vascular indications
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.